Home

QoL

Read time: 3 min

Steps towards more effective and better tolerated treatment options for schizophrenia

New more effective and better tolerated treatments for schizophrenia are needed to improve patient...

Depression, Schizophrenia

Read time: 3 min

Congress highlights

Why do we need new treatments for major depressive disorder and schizophrenia?

Atypical antipsychotics are the mainstay of treatment for schizophrenia and a therapeutic option as...

Read time: 3 min

Collaborative care for comorbid depression: cost-effectiveness and implementation

Collaborative care (CC) is a care model for patients with comorbid depression and chronic disease...

Read time: 1 min

Control of side effects may be the key to solving the dopamine paradox of schizophrenia

Schizophrenia is a highly complex and heterogeneous disease that consists of positive symptoms,...

Read time: 3 min

Congress highlights

Treatment-resistant schizophrenia and the impact on caregivers: A focus group study

Treatment-resistant schizophrenia (TRS), clinically defined as failure to respond to two trials of...

Parity of Care – People with poor mental health deserve access to health services on par with physical health services

There is no health without mental health. Yet, despite the burden of poor mental health worldwide,...

Alzheimer's Disease

Read time: 3 min

Agitation should be a focus in dementia

In the past, “agitation” in the context of the dementias referred to a wide range of...

Read time: 3 min

Mind the gap

We look into new approaches to fill the gap between clinical remission and functional recovery in...

Read time: 1 min

Light in the darkness: Combating the mid-winter blues

Social, cultural, and even climatic factors can make the winter holidays particularly difficult for...

Read time: 2 min

The impact and challenges of cognitive impairments - Interview with Kamilla Miskowiak

An interview with Kamilla Miskowiak, of the University Hospital, Copenhagen, Denmark

Depression, Schizophrenia

Read time: 4 min

Congress highlights

Love is all we need

Gender dysphoria was a central topic at the EPA 2017 symposium on love, sex and psychiatry. We were...

Read time: 3 min

Congress highlights

Searching for (possible) schizophrenia subtypes and markers

At the EPA 2017 symposium on subtypes of schizophrenia, we were presented with the novel hypothesis...

Country selection

We are registering that you are located in Brazil - if that's correct then please continue to Progress in Mind Brazil

Not located in Brazil?
Go to a different regional HUB

Continue to Progress in Mind Continue to Progress in Mind Brazil Continue to Progress in Mind Spain Continue to Progress in Mind Italy Continue to Progress in Mind

You are leaving Progress in Mind

Continue to

Cancel

Hello
Please confirm your email

We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.

The information on this site is exclusively intented for health care professionals.

All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.

Accept

Decline

Congress

Register for access to Progress in Mind in your country